RetractedTrialThe Journal of biological chemistry2013

Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

Tzu-Hua Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.